Develops ophthalmic drug delivery technology (Optejet). Manages a cryptocurrency treasury denominated in HYPE tokens. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 51% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $813K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 18 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $45.3M against $813K in annual sales.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, HYPD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HYPD is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (60/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.